Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
Previous Symbol
CUSIPN/A
Phone650-213-8444
Debt
Debt-to-Equity RatioN/A
Current Ratio6.86
Quick Ratio6.86
Price-To-Earnings
Trailing P/E Ratio-1.52
Forward P/E Ratio-1.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.45 million
Price / Sales30.27
Cash FlowN/A
Price / CashN/A
Book Value$1.38 per share
Price / Book1.49
Profitability
EPS (Most Recent Fiscal Year)($1.35)
Net Income$-15,660,000.00
Net MarginsN/A
Return on Equity-78.97%
Return on Assets-51.79%
Miscellaneous
Employees18
Outstanding Shares21,410,000
Market Cap$46.68 million
OptionableNot Optionable
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Shares of Soleno Therapeutics reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics Inc (NASDAQ:SLNO) released its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.12. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
3 Wall Street analysts have issued twelve-month price objectives for Soleno Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate Soleno Therapeutics' share price to reach $7.3333 in the next twelve months. This suggests a possible upside of 257.7% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.
What is the consensus analysts' recommendation for Soleno Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.
What are Wall Street analysts saying about Soleno Therapeutics stock?
Here are some recent quotes from research analysts about Soleno Therapeutics stock:
- 1. According to Zacks Investment Research, "Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief. Soleno Therapeutics Inc., formerly known as Capnia Inc., is based in Vancouver, Canada. " (11/8/2018)
- 2. Maxim Group analysts commented, "Soleno announced that it will present two poster presentations on 57 th Athens, Greece. The late-breaking posters will show PK and clinical data as well as the glycemic impact of diazoxide chloride controlled release (DCCR) use, long- term, in Prader-Willi Syndrome (PWS). Conclusion: We view the posters as an opportunity to showcase the potential benefit of DCCR in PWS in the EU. Focus remains on the Phase 3 trial of DCCR in PWS which is enrolling, data in 1H19." (9/17/2018)
Has Soleno Therapeutics been receiving favorable news coverage?
News coverage about SLNO stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Soleno Therapeutics earned a daily sentiment score of 0.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include Fonar (FONR), Second Sight Medical Products (EYES), Zynex (ZYXI), Viveve Medical (VIVE), Stereotaxis (STXS), Edap Tms (EDAP), IRIDEX (IRIX), ENDRA Life Sciences (NDRA), Digirad (DRAD), Precision Optics (PEYE), Aradigm (ARDM), CHF Solutions (CHFS), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU) and Escalon Medical (ESMC).
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO & Director (Age 48)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 56)
- Mr. David D. O'Toole, Consultant (Age 59)
- Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 68)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $2.05.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $46.68 million and generates $1.45 million in revenue each year. The company earns $-15,660,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Soleno Therapeutics employs 18 workers across the globe.
What is Soleno Therapeutics' official website?
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
